Postoperative atrial fibrillation predicts long-term survival after aortic-valve surgery but not after mitral-valve surgery: a retrospective study

Nicolas Girerd, Julien Magne, Philippe Pibarot, Pierre Voisine, François Dagenais, Patrick Mathieu

ABSTRACT

Background: Postoperative atrial fibrillation (POAF) has been reported to be associated with reduced long-term survival after isolated coronary artery bypass grafting surgery. The objective of this study was to determine the impact of POAF on long-term survival after valvular surgery.

Methods: The authors retrospectively analysed the preoperative and operative data of 2986 consecutive patients with no preoperative history of atrial fibrillation undergoing first valvular surgery (aortic-valve replacement (AVR), mitral valve replacement or mitral valve repair (MVR/MVRp) with or without coronary artery bypass grafting surgery) in their institution between 1995 and 2008 (median follow-up 5.31 years, range 0.1–15.0). The authors investigated the impact of POAF on survival using multivariable Cox regression.

Results: Patients with POAF were older, and were more likely to have hypertension or renal failure when compared with patients without POAF. The 12-year survival in patients with POAF was 45.7 ± 2.8% versus 61.4 ± 2.1% in patients without POAF (p < 0.001). On a multivariable analysis, when adjusting for age and other potential confounding factors, POAF tended to be associated with lower long-term survival (HR for all-cause death (HR) = 1.17, 95% CI 1.00 to 1.38, p = 0.051). The authors also analysed this association separately in patients with AVR and those with MVR/MVRp. In the multivariable analysis, POAF was a significant predictor of death in patients with AVR (HR = 1.22, CI 1.02 to 1.45, p = 0.03) but not in patients with MVR/MVRp (HR = 0.87, CI 0.58 to 1.29, p = 0.48).

Conclusions: POAF is significantly associated with long-term mortality following AVR but not after MVR/MVRp. The underlying factors involved in the pathogenesis of POAF after MVR/MVRp may partially account for the lack of association between POAF and survival in these patients.

INTRODUCTION

Postoperative atrial fibrillation (POAF) is the most frequent complication following cardiac surgery. Indeed, POAF occurs in 20–50% of patients, depending on the type of surgical procedure.1 POAF is associated with higher morbidity, prolonged hospitalisation and increased hospital costs following cardiac surgery.1 However, conflicting results have been reported regarding the impact of POAF on early postoperative mortality.2–4 Moreover, recent studies have shown that POAF is associated with reduced long-term survival after isolated coronary artery bypass grafting surgery (CABG) in several large observational studies.4–8 Nonetheless, in the context of valvular surgery, few studies have examined the impact of POAF on long-term survival, and these studies have yielded conflicting results.6–9 Mariscalco and Enghorn8 reported that POAF is associated with lower survival after CABG but not after valvular surgery, whereas Filardo et al.9 found that POAF is significantly associated with increased long-term risk of mortality after aortic-valve replacement (AVR).
The objective of this study was thus to examine the impact of POAF on long-term mortality after valvular surgery in a large cohort of patients. Further, we determined whether the impact of POAF on survival following valvular surgery was influenced by the treated valve (aortic or mitral) or the presence of concomitant coronary artery disease (CAD) requiring CABG.

**METHODS**

**Study population**

Data on 2986 patients with no preoperative history of paroxysmal or chronic atrial fibrillation (AF) operated on for a first valvular surgery at the Quebec Heart & Lung Institute between 1995 and 2008 were prospectively collected in a computerised database and then retrospectively analysed. Patients with AVR, mitral valve replacement (MVR) and mitral valve repair (MVRp) were included. Previous or associated CABG was not considered as an exclusion criterion. Patients with at least one of the following criteria were excluded: (1) concomitant cardiac or vascular procedure (including tricuspid and pulmonary-valve surgery), (2) double-valve procedure (concomitant mitral and aortic-valve surgery), (3) previous valvular surgery and (4) short-term mortality (defined as death from any cause within 30 days after operation if the patient was discharged from hospital or within any interval if the patient was not discharged). The study was approved by the Institutional Review Board of Quebec Heart & Lung Institute.

**Detection and treatment of AF**

Detailed information regarding the detection and treatment of POAF in our institution was previously reported. Briefly, POAF was defined as any sustained episode recorded during the postoperative hospital stay and requiring medical and/or electrical cardioversion. No systematic prophylactic measures were used to prevent the development of POAF. However, as a general rule, unless contraindicated, β-blocker medication was introduced (or reintroduced) in all patients within the first 24 h after surgery. A constant ambulatory electrocardiographic (ECG) monitoring was performed in all patients during the first 48 h after surgery. Thereafter, a standard daily 12-lead ECG was recorded. In every patient suspected of an arrhythmic event, a standard 12-lead ECG was performed and the patient was monitored with continuous ambulatory ECG until 48 h after the resolution of the arrhythmia. All patients with POAF were treated with intravenous amiodarone as a first-line therapy. When needed, electrical cardioversion was performed.

**Outcome**

Long-term survival data were obtained from the death certificates of the Registry Office of the Quebec government. All-cause mortality was analysed. Survival follow-up was closed on 31 December 2009.

**Statistical analysis**

Continuous variables were expressed as mean or median ± SD and were compared using t tests for independent samples. Differences in proportion were compared using a $\chi^2$ test. We used the Kaplan–Meier method to estimate survivals. Differences between survival curves were analysed using the logrank test. The association between POAF and risk of all-cause was examined using individual and multivariable Cox proportional hazard models. In the multivariable model, we adjusted for the following potential confounders: age, gender, diabetes, hypertension, renal failure, chronic obstructive pulmonary disease, previous myocardial infarction, previous stroke, current smoking status and left ventricular systolic dysfunction defined as left-ventricular ejection fraction <50%. The choice of the covariates was based on current available evidence in the field of cardiac surgery rather than data-driven. Multiplicative interaction with POAF was tested for the following predefined variables: type of surgical procedure, type of underlying valvular dysfunction (regurgitation vs stenosis), severity of CAD and mechanical-valve implantation. A probability value < 0.05 was considered significant. All statistical analyses were performed with SPSS V.15.

**RESULTS**

**Baseline characteristics of patients with and without POAF**

Patients with POAF were older ($p=0.001$) and had a higher prevalence of hypertension ($p=0.03$) and renal failure ($p=0.001$) (table 1). Patients receiving mechanical valves or current smokers were less likely to have POAF ($p=0.004$ and < 0.001 respectively).

**Impact of POAF on long-term survival in the whole cohort**

The median follow-up was 5.31 years (range: 0.1–15.0 years). Overall, 705 patients (23.6%) died. The 6- and 12-year survival in patients with and without POAF were $78.1 \pm 1.3\%$ and $45.7 \pm 2.8\%$ versus $83.6 \pm 1.0\%$ and $61.4 \pm 2.1\%$, respectively ($p<0.001$, figure 1).

On multivariable analysis, when adjusting for age and other potential confounding factors, POAF tended to be associated with long-term survival (HR=1.17, 95% CI 1.00 to 1.38, $p=0.051$) (table 2).

There was no significant interaction with concomitant CABG, three-vessel disease or mechanical-valve implantation (all $p>0.20$). Of note, the interaction with the type of valvular procedure (aortic-valve surgery versus mitral-valve surgery) was of borderline statistical significance ($p=0.09$). Consequently, we also report results in subsets of patients with AVR or with MVR–MVRp.

**Baseline characteristics of patients with and without POAF in patients with aortic-valve surgery and in patients with mitral-valve surgery**

Patients with POAF were older and had a higher prevalence of renal failure regardless of the surgical procedure (table 1). Patients with hypertension and patients implanted with mechanical valves were more likely to...
<table>
<thead>
<tr>
<th></th>
<th>Whole cohort, n = 2986</th>
<th></th>
<th>Patients undergoing aortic-valve replacement, n = 2287</th>
<th></th>
<th>Patients undergoing mitral-valve surgery, n = 699</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>POAF (%)</td>
<td>No POAF (%)</td>
<td>p Value</td>
<td>POAF (%)</td>
<td>No POAF (%)</td>
<td>p Value</td>
</tr>
<tr>
<td>Age (years)</td>
<td>70.4±9.3</td>
<td>66.1±11.0</td>
<td>&lt;0.001</td>
<td>71.8±8.3</td>
<td>67.7±10.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female gender</td>
<td>38.8%</td>
<td>36.7%</td>
<td>0.23</td>
<td>36.6%</td>
<td>37.3%</td>
<td>0.74</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>23.5%</td>
<td>22.3%</td>
<td>0.44</td>
<td>25.3%</td>
<td>24.0%</td>
<td>0.50</td>
</tr>
<tr>
<td>Hypertension</td>
<td>61.4%</td>
<td>57.4%</td>
<td>0.03</td>
<td>65.2%</td>
<td>60.5%</td>
<td>0.02</td>
</tr>
<tr>
<td>Renal failure</td>
<td>9.1%</td>
<td>5.8%</td>
<td>0.001</td>
<td>8.4%</td>
<td>5.4%</td>
<td>0.004</td>
</tr>
<tr>
<td>Chronic obstructive</td>
<td>17.1%</td>
<td>15.0%</td>
<td>0.12</td>
<td>18.2%</td>
<td>15.1%</td>
<td>0.05</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>23.9%</td>
<td>22.7%</td>
<td>0.45</td>
<td>20.8%</td>
<td>19.2%</td>
<td>0.35</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>7.3%</td>
<td>6.1%</td>
<td>0.21</td>
<td>7.3%</td>
<td>6.7%</td>
<td>0.63</td>
</tr>
<tr>
<td>Current smoking status</td>
<td>10.5%</td>
<td>16.1%</td>
<td>&lt;0.001</td>
<td>10.0%</td>
<td>13.5%</td>
<td>0.01</td>
</tr>
<tr>
<td>Left-ventricular ejection</td>
<td>20.6%</td>
<td>18.0%</td>
<td>0.08</td>
<td>18.4%</td>
<td>14.6%</td>
<td>0.02</td>
</tr>
<tr>
<td>Fraction &lt;50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical valve implanted</td>
<td>18.2%</td>
<td>22.5%</td>
<td>0.004</td>
<td>10.0%</td>
<td>18.0%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Dominant valve dysfunction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>64.0%</td>
<td>68.7%</td>
<td>0.01</td>
<td>86.3%</td>
<td>87.6%</td>
<td>0.35</td>
</tr>
<tr>
<td>Aortic regurgitation</td>
<td>10.1%</td>
<td>9.7%</td>
<td></td>
<td>13.7%</td>
<td>12.4%</td>
<td></td>
</tr>
<tr>
<td>Mitral stenosis</td>
<td>3.7%</td>
<td>2.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitral regurgitation</td>
<td>22.2%</td>
<td>19.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary-artery disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Three-vessel disease</td>
<td>16.0%</td>
<td>17.7%</td>
<td>0.30</td>
<td>14.8%</td>
<td>15.9%</td>
<td>0.50</td>
</tr>
<tr>
<td>Previous coronary-artery bypass grafting</td>
<td>4.4%</td>
<td>5.6%</td>
<td>0.12</td>
<td>4.0%</td>
<td>6.1%</td>
<td>0.02</td>
</tr>
<tr>
<td>Concomitant coronary-artery bypass grafting</td>
<td>49.1%</td>
<td>47.6%</td>
<td>0.43</td>
<td>48.9%</td>
<td>48.4%</td>
<td>0.83</td>
</tr>
</tbody>
</table>

Table 1 Baseline characteristics in the whole cohort and in patients with aortic or mitral-valve surgery according to presence or absence of postoperative atrial fibrillation (POAF)
have POAF after aortic-valve surgery (p=0.02 and p<0.001 respectively), but not after mitral-valve surgery (p=0.21 and p=0.45 respectively). Current smokers were, in both groups, less likely to have POAF (p<0.001).

Impact of POAF on long-term survival in patients with aortic-valve surgery and in patients with mitral-valve surgery

On individual analysis, POAF was associated with reduced long-term survival in patients who underwent AVR (75.9±1.6% vs 82.6±1.2% at 6 years, p<0.001, figure 1), whereas no significant difference was observed in patients with MVR or MVRp (84.4±2.4% vs 87.8±2.0%, p=0.40).

In the multivariable analysis (table 2), POAF remained a significant predictor of long-term mortality in patients with AVR (HR=1.22, CI 1.02 to 1.45, p=0.03). POAF was not significantly associated with survival in patients with MVR or MVRp (HR=0.87, CI 0.58 to 1.29, p=0.48).

DISCUSSION

The major finding of this study is that POAF following valvular surgery is associated with long-term mortality in patients with AVR but not in those with MVR or MVRp.

Impact of POAF on long-term survival in patients with valvular surgery

Mariscalco and Engstrom found no significant association between POAF and long-term survival following valvular surgery, whereas Filardo et al reported that POAF after AVR is significantly associated with long-term mortality independently of the preoperative disease severity. Our results are highly consistent with both studies. Indeed, the association between POAF and survival was only borderline in the whole cohort, largely driven by the significant association with survival in patients with AVR. In patients who underwent mitral-valve surgery, we did not find a significant impact of POAF on long-term survival. Our results thus suggest that the lack of association between POAF and survival reported in the study of Mariscalco and Engstrom might be due to the inclusion of a mixed group of patients who underwent AVR and/or mitral surgery. Furthermore, our study has more statistical power than the two reports previously published. The association reported in the study of Mariscalco and Engstrom (HR=1.21, CI 0.92 to 1.58) which included 995 patients with isolated valvular surgery would probably have been statistically significant in a sample of patients as large as ours.

Figure 1 Long-term survival in patients with or without postoperative atrial fibrillation (POAF) in the whole cohort and in subsets of patients defined according to the type of valvular procedure.
It remains unclear why the significance of the association between POAF and survival differs markedly according to the type of valvular procedure. In our population, patients with AVR were mainly patients with severe aortic stenosis. As aortic stenosis shares some physiopathology similarities with CAD, the association of POAF with long-term survival in patients with AVR appears consistent with the significant association between POAF and long-term survival after isolated CABG.4–8 The lack of significant association between POAF and long-term survival after MVR or MVRp may be explained, at least in part, by differences in the factors and mechanisms involved in the pathogenesis of POAF in patients with mitral surgery versus patients with AVR and/or CABG. The determinants of POAF in patients with mitral-valve surgery are largely unknown. To the best of our knowledge, there is no specific study focusing on the prediction of the risk for POAF after mitral-valve surgery. On the other hand, inflammation appears to be the key determinant of POAF following CABG.11–14 Consistently, pharmacological interventions targeting postoperative inflammation such as glucocorticoids have been shown to reduce the incidence of POAF after CABG.15 Hence, POAF after isolated CABG and AVR could be a marker of exaggerated inflammatory response to stress, which would in turn translate into a higher incidence of perioperative morbidity and long-term mortality. In contrast, POAF after mitral-valve surgery might be linked to the preoperative features of mitral valve disease (left atrial dilation and hypertension, etc), which are, at least in part, corrected by surgery. This hypothesis has to be tested in future studies. In particular, mechanistic studies specifically focusing on the pathogenesis of POAF after aortic and mitral-valve surgery are needed.

Lack of association even in patients without long-term indication for warfarin

It has been previously hypothesised that POAF might have a weaker effect after valvular surgery because of the indication of lifelong warfarin therapy after mechanical-valve implantation.6 In line with this hypothesis, the long-term anticoagulation instituted at the time of mechanical-valve AVR would prevent embolism related to atrial fibrillation recurrence, thus reducing the impact of POAF on survival. The results of a large observational study recently supported this hypothesis.8 In this study, anticoagulant treatment at discharge was associated with decreased long-term mortality in patients who experience POAF after isolated CABG. However, in our cohort, there was no significant interaction between the association of POAF with survival and an indication for long-term warfarin treatment (ie, patients with mechanical valves). This lack of modifying effect of lifetime warfarin treatment would argue against the hypothesis that the lack of impact of POAF after mitral valvular surgery is due to the anticoagulation needed for mechanical valves.

Clinical implications

According to our results, POAF is a significant predictor of long-term survival after isolated or combined AVR. Consequently, patients with POAF after AVR should be considered at increased risk for longer-term events. Hence, additional specific intervention, possibly a closer follow-up, should be considered in these patients.

Limitations

This is a large retrospective monocentre observational study. As in any observational study, causality between POAF after AVR and mortality cannot be ascertained. POAF might be a marker of underlying myocardial disease, or other conditions, which are associated with poorer outcome. Besides, the mechanisms involved in the poorer survival of patients with POAF remain uncertain. Postdischarge atrial fibrillation recurrence could be implicated in this excess of mortality. We unfortunately do not have the data regarding postdischarge arrhythmia recurrences. Because of these limitations, the mechanisms by which mortality is explained by postoperative AF remain speculative, and the causative link between POAF and survival is still uncertain.
We had no precise information regarding the post-discharge management of POAF. Medications introduced after the episode of POAF may have influenced our analysis. However, as a general rule, only recurrent or sustained episodes of AF after the postoperative period are treated by long-term anticoagulant therapy or antiarrhythmic drugs. Considering the relatively low proportion of patients with persistent AF after the early postoperative period, this residual confounding probably has a minimal impact on the results.

Constant ECG monitoring was performed only during the first 48 h after surgery. Asymptomatic episodes or transient episodes of POAF after the first 48 h after surgery might consequently have been underdiagnosed. This misclassification might have biased the results. Besides, no conclusions can be drawn from our results regarding the significance of asymptomatic POAF.

**Conclusion**
This study demonstrates that POAF is associated with long-term mortality in patients with AVR but not in those with mitral-valve surgery. The underlying factors involved in the pathogenesis of POAF after mitral-valve surgery may account for this lack of impact of POAF on survival in these patients.

**Funding** This work was supported by the Quebec Heart and Lung Institute Foundation.

**Competing interests** None.

**Ethics approval** Ethics approval was provided by the Institutional Review Board of Quebec Heart & Lung Institute.

**Contributors** NG performed the statistical analyses and drafted the manuscript; JM participated in the interpretation of the data and critically reviewed the manuscript; PP, PV and FD critically reviewed the manuscript and participated in the interpretation of the data; PM participated in the design of the study, interpretation of the data and critical review of the manuscript.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data available.

**REFERENCES**